Arca
Skip to content
Tools
Tools

Chronic myelomonocytic leukemia (CMML-2)

Drug research and approvals for chronic myelomonocytic leukemia (CMML-2): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 4 studies of chronic myelomonocytic leukemia (CMML-2) are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 1 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 4
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 4 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 2

  • AzacitidineDNA (cytosine-5)-methyltransferase 3A inhibitor
  • DecitabineDNA (cytosine-5)-methyltransferase 3A inhibitor

Phase 3 12 of 13

Phase 2 10

Phase 1 or earlier 10

How its trials ended

316 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 77 whose ending is known, 39% met their primary endpoint, 4% missed it and 57% stopped early.

  • Completed, result not reported13041%
  • Ongoing9931%
  • Met its primary endpoint309%
  • Stopped: other or unclear206%
  • Status unknown103%
  • Stopped: enrollment or feasibility72%
  • Stopped: lack of efficacy62%
  • Stopped: funding62%
  • Stopped: sponsor or business decision52%
  • Missed its primary endpoint31%

Trials authorized in Canada

Newest first; search them all in Canada trials
Sep 7, 2023Protocol 10538, venetoclax in combination with ASTX727, an all-oral therapy for chronic myelomonocytic leukemia and other MDS/mpn with excess blasts…ASTX727 (cedazuridine-decitabine)/ VenetoclaxUniversity Health NetworkOngoing
May 31, 2023A phase 1, open-label, multicenter, dose escalation study of PRT1419 injection as monotherapy or in combination with azacitidine or venetoclax in patients with…PRT1419 / Venetoclax / AzacitidinePrelude TherapeuticsClosed
Jun 30, 2021A multiphase, pharmacokinetics, safety, and efficacy study of ASTX030 (azacitidine and cedazuridine) as monotherapy in subjects with myeloid neoplasm or in…Azacitidine-cedazuridine (ASTX030) / Azacitidine / CedazuridineTaiho OncologyOngoing
Jan 6, 2021Phase 1b/2 open-label, multicenter, dose optimization clinical study of the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of cfi…CFI-400945Treadwell Therapeutics, Inc.Ongoing
Mar 6, 2020A randomized, double-blind, placebo-controlled phase III multi-center study of azacitidine with or without MBG453 for the treatment of patients with…MBG453Novartis PharmaceuticalsClosed
May 8, 2018An open-label, multicenter, extension study for subjects who participated in prior guadecitabine clinical studiesGuadecitabine (SGI-110)Astex Pharmaceuticals Inc.Closed
May 7, 2018A phase 3, randomized, controlled, open-label, clinical study of pevonedistat plus azacitidine versus single-agent azacitidine as first-line treatment for…Pevonedistat (MLN4924) / AzacitidineTakeda Pharmaceuticals USAOngoing
Aug 18, 2016A phase 3, multicenter, randomized, open-label study of guadecitabine (SGI-110) versus treatment choice in adults with myelodysplastic syndromes (MDS) or…Guadecitabine (SGI-110)Astex Pharmaceuticals Inc.Closed
Feb 8, 2016A phase 2, randomized, controlled, open-label, clinical study of the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in…Pevonedistat / AzacitidineTakeda Pharmaceuticals USAClosed

FDA orphan designations

Approved first, then open designations, newest first
Jul 7, 2020InqoviIndicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and…Astex Pharmaceuticals, Inc.Approved
Oct 21, 2026OnvansertibTreatment of chronic myelomonocytic leukemia (CMML)Cardiff Oncology Inc.Designated
Feb 25, 2025Co-packaged combination of azacitidine and cedazuridineTreatment of chronic myelomonocytic leukemia (CMML)Taiho Oncology, Inc.Designated
Feb 8, 2024Recombinant, humanized immunoglobulin G1 monoclonal…Treatment of Chronic Myelomonocytic LeukemiaImmune-Onc TherapeuticsDesignated
Nov 7, 2023Recombinant human signal regulating protein alpha…Treatment of chronic myelomonocytic leukemiaImmuneOnco Biopharmaceuticals (Shanghai) Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.